191425-55-5

Basic information

• Product Name: L-Phenylalanine, N-[(4-nitrophenoxy)carbonyl]-, 1,1-dimethylethyl ester
• CAS NO: 191425-55-5
• Molecular Formula: C20H22N2O6
• Molecular Weight: 386.404
• Mol File: 191425-55-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: L-Phenylalanine, N-[(4-nitrophenoxy)carbonyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Phenylalanine, N-[(4-nitrophenoxy)carbonyl]-, 1,1-dimethylethyl ester(191425-55-5)
• EPA Substance Registry System: L-Phenylalanine, N-[(4-nitrophenoxy)carbonyl]-, 1,1-dimethylethyl ester(191425-55-5)

Safety Data

• Hazardous Substances Data: 191425-55-5(Hazardous Substances Data)

Upstream product

• 15100-75-1 L-phenylalanine tert-butyl ester hydrochloride 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 16874-17-2 L-phenylalanine tert-butyl ester 
• 5070-13-3 bis-(p-nitrophenyl) carbonate 

Downstream Products

• 1138406-13-9 4'-O-(CO-Phe-OtBu)-quercetin 
• 1138406-41-3 3′-O-CO-(Phe-OtBu)quercetin 
• 1138406-20-8 4'-O-(CO-Phe-OH)-quercetin 
• 1138406-28-6 3'-O-(CO-Phe-OH)-quercetin 
• 1270004-51-7 4'-O-CO-(Phe-OtBu)-tricin 

Relevant articles and documents

Traversal of the Blood-Brain Barrier by Cleavable l -Lysine Conjugates of Apigenin

Apigenin, a flavone abundant in parsley and celery, is known to act on several CNS receptors, but its very poor water solubility (a temporary sedative effect on the mice within 5 min of intraperitoneal administration (single dose of 0.4 mg/g) and could be detected in the mice brain tissues at a concentration of 0.82 μg/g of intact Lys-apigenin carbamate 10 and 0.42 ug/g of apigenin at 1.5 h. This study accomplished the delivery of apigenin across the BBB in a manner that might be applicable to other congeners, which should inform the future development of BBB-crossing flavonoids.

CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS

The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.

Heterocyclic derivatives with immunomodulatory effects

The invention relates to novel heterocyclic derivatives with immunomodulatory effects capable of inhibiting therapeutic agents in a programmed cell death (PD1) signal path. The compounds disclosed bythe invention are capable of enhancing antitumor activit